Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Solid Tumor × marizomib × Clear all

Status

No longer available 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Multiple Myeloma 4 Recurrence 2 Lymphoma 2 Glioma 2 Glioblastoma 2 Brain Neoplasms 2 Solid Tumor 1 Pancreatic Neoplasms 1 Neoplasms, Plasma Cell 1 Melanoma 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, B-Cell, Marginal Zone 1 Leukemia 1 Gliosarcoma 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Injections 11 pembrolizumab 9 Paclitaxel 8 senaparib 7 Docetaxel 7 Nivolumab 6 Cisplatin 5 Capecitabine 5 toripalimab 4 atezolizumab 4 Ipilimumab 4 Gemcitabine 4 tislelizumab 3 Rifampin 3 Itraconazole 3 Carboplatin 3 Bevacizumab 3 130-nm albumin-bound paclitaxel 3 zimberelimab 2 sintilimab 2 pertuzumab 2 ontuxizumab 2 magrolimab 2 fluzoparib 2 famitinib 2 durvalumab 2 camrelizumab 2 alpha-Synuclein 2 Oxaliplatin 2 Midazolam 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04644107 2020-11-25

Expanded Access for Marizomib

Celgene

No longer available

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡